Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a share repurchase on 3 June 2026, retiring 106,600 H-shares via on-market transactions. The repurchase was executed at prices ranging from HKD 15.25 to HKD 16.30 per share, with a volume-weighted average cost of HKD 15.89, for a total outlay of HKD 1.69 million.

Following the transaction, issued shares outstanding (excluding treasury stock) fell 0.05 % to 224.03 million, while treasury shares increased to 3.05 million. Total issued share capital remains unchanged at 227.07 million shares.

The buyback forms part of the mandate approved on 29 May 2026, which authorises the company to repurchase up to 22.44 million shares. Cumulative purchases under this mandate now stand at 0.34 million shares, equivalent to 0.15 % of the share count on the mandate date. A 30-day moratorium on new share issuance or treasury-share sales runs through 3 July 2026, in accordance with Hong Kong Stock Exchange rules.